Fig. 2From: Accumulation of copy number alterations and clinical progression across advanced prostate cancerAssociation of copy number alteration with clinical outcome measures. A–D Cox survival model demonstrating adjusted estimate of impact of burden of copy number (CN) alteration as a continuous variable on hazard of A failure-free survival; B metastatic progression-free survival; C prostate cancer-specific survival; D overall survival. Variables included in adjusted analysis: (1) grading group; (2) metastatic state (M0N0, M0N1, M1 low and M1 high); (3) Pre-ADT serum PSA log transformed; (4) age at randomisation; (5) tumour cellularity (%). Black line represents the impact of the burden of copy number alteration on relative risk for 284/300 patients for which we could determine disease state (16 M1 patients with unknown designation for low versus high volume were excluded). Each coloured line represents sub-groups of the CN-300 cohort defined by metastatic state. E–H Kaplan-Meier estimates. CN-300 cohort split into quartile groups determined by the burden of copy number alteration. Time-to event; E failure-free survival; F metastatic progression-free survival; G prostate cancer-specific survival; H overall survivalBack to article page